Cascadian Therapeutics, Inc.
(NASDAQ : ONTY)

( )
ONTY PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
DHRDanaher Corp.
-1.87%140.310.7%$420.97m
MDTMedtronic Plc
-0.26%110.930.6%$415.71m
ABTAbbott Laboratories
-1.70%84.250.8%$395.60m
TMOThermo Fisher Scientific, Inc.
-2.10%300.381.0%$360.95m
BDXBecton, Dickinson & Co.
-2.01%243.321.1%$337.37m
SYKStryker Corp.
-0.61%205.001.3%$335.02m
BAXBaxter International, Inc.
-0.39%81.121.8%$322.46m
ISRGIntuitive Surgical, Inc.
-0.08%569.092.4%$317.50m
BSXBoston Scientific Corp.
-0.02%42.301.1%$301.24m
EWEdwards Lifesciences Corp.
-1.32%242.411.2%$282.22m
ALGNAlign Technology, Inc.
1.74%268.516.4%$266.82m
WMGIWright Medical Group NV
-0.20%29.458.3%$265.88m
DXCMDexCom, Inc.
2.60%213.788.3%$259.65m
PODDInsulet Corp.
1.19%182.496.7%$148.39m
ABMDABIOMED, Inc.
-20.22%178.093.3%$143.28m

Company Profile

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.